| Pan-cancer analysis of whole genomes. S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ... Nature 578 (DKFZ-2020-01051), 82-93, 2020 | 1656* | 2020 |
| Whole-genome landscapes of major melanoma subtypes NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ... Nature 545 (7653), 175-180, 2017 | 1257 | 2017 |
| CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ... Nature 549 (7670), 101-105, 2017 | 737 | 2017 |
| Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ... Science 367 (6478), 2020 | 323 | 2020 |
| A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients J Cursons, F Souza-Fonseca-Guimaraes, M Foroutan, A Anderson, ... Cancer immunology research 7 (7), 1162-1174, 2019 | 211 | 2019 |
| Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations SCH Tsao, J Weiss, C Hudson, C Christophi, J Cebon, A Behren, ... Scientific reports 5 (1), 1-11, 2015 | 188 | 2015 |
| Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ... Jama Oncology 6 (9), 1405-1409, 2020 | 176 | 2020 |
| BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ... Cell Death & Disease 10 (5), 342, 2019 | 155 | 2019 |
| BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage VJ Mar, SQ Wong, J Li, RA Scolyer, C McLean, AT Papenfuss, RW Tothill, ... Clinical Cancer Research 19 (17), 4589-4598, 2013 | 153 | 2013 |
| Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma A Jayachandran, M Anaka, P Prithviraj, C Hudson, SJ McKeown, PH Lo, ... Oncotarget 5 (14), 5782, 2014 | 138 | 2014 |
| Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers O Klein, D Kee, B Markman, M Michael, CR Underhill, MS Carlino, ... Clinical Cancer Research, 2020 | 134 | 2020 |
| Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma N Jacquelot, C Seillet, M Wang, A Pizzolla, Y Liao, S Hediyeh-Zadeh, ... Nature immunology 22 (7), 851-864, 2021 | 120 | 2021 |
| Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma J Wang, A Wuethrich, AAI Sina, RE Lane, LL Lin, Y Wang, J Cebon, ... Science Advances 6 (9), eaax3223, 2020 | 115 | 2020 |
| Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma H Halse, AJ Colebatch, P Petrone, MA Henderson, JK Mills, H Snow, ... Scientific reports 8 (1), 1-14, 2018 | 111 | 2018 |
| Characterising the phenotypic evolution of circulating tumour cells during treatment SCH Tsao, J Wang, Y Wang, A Behren, J Cebon, M Trau Nature communications 9 (1), 1482, 2018 | 99 | 2018 |
| A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy J Li, A Wuethrich, AAI Sina, HH Cheng, Y Wang, A Behren, ... Nature communications 12 (1), 1087, 2021 | 78 | 2021 |
| Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ LJ Vella, A Behren, B Coleman, DW Greening, AF Hill, J Cebon Neoplasia 19 (11), 932-940, 2017 | 64 | 2017 |
| Autoantibodies may predict immune-related toxicity: results from a phase I study of Intralesional Bacillus Calmette-Guerin followed by ipilimumab in patients with advanced … J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ... Frontiers in Immunology 9, 411, 2018 | 60 | 2018 |
| FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. BS Tan, M Anaka, S Deb, C Freyer, LM Ebert, AC Chueh, S Al-Obaidi, ... Oncotarget 5 (1), 264, 2014 | 59 | 2014 |
| PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation CSA Tutuka, MC Andrews, JM Mariadason, P Ioannidis, C Hudson, ... Molecular Cancer 16 (1), 112, 2017 | 58 | 2017 |
Jonathan CebonOlivia Newton-John Cancer Research InstituteVerified email at onjcri.org.au
